Related to Overview of the Number Three and Four Biotech Clusters in the U.S.

• Obama Budget Greeted with Kudos Along with a Few Concerns
  While basic research is getting a boost, industry advocates point out that small biotech are still struggling.
  
• 2011 Budget Outlook: Trim, Cut, Then Slash
  Agencies like the FDA and NIH are looking at potentially huge cuts.
  
• Study Finds a Friend at NIH but Will Congress Share the Love?
  Paper in NEJM tries to make case for boosting federal research funding amid House leaders’ pursuit of spending cuts.
  
• NY Biotech Leaders Pursue Empire State of Mind with One-Stop Shop Proposal
  Think tank is also promoting tax credit extensions, tailored incentives, and easier tech transfer as cures for state’s life science blues.
  
• Obama Administration’s Support During 2011 for Biotech Yields Mixed Results
  President had success with finalizing patent reform after decades of debate but still has to address other concerns like the budget.
  
• Republican Candidates Vouch for Agency Spending Cuts and hESC Restrictions
  While details differ, Romney, Gingrich, Santorum, and Paul all want to slice FDA and NIH’s budget.
  
• As Politicos Posture, Advocates Assess the Impact of Sequestration on Federal Agencies
  NIH estimates a 7.8% cut, while FASEB projects that number could go as high as 11.1%.
  
• Top 20 Pharma-Friendly Congress Members
  Who accepted the biggest pharmaceutical company contributions? Find out here.
  
• Candidates’ Science Answers Raise More Questions
  Presidental candidates’ responses to ScienceDebate.org query are inadequate and more discussion is essential.
  
• Drug Companies Exert Greater Influence on Development
  Government funding, once the norm, is declining and pharma firms are in the driver’s seat.
  
• SBIR Thinks Smaller
  New rules taking effect on January 28 aim to draw investor-owned smaller biopharmas to the federal grant program and STTR, its companion.
  
• DNA Collection v. DNA Privacy
  Supreme Court weighs constitutionality of taking samples from arrested suspects absent a conviction.
  
• GEN Congressional Hall of Fame
  Biomedical research has friends in high places. Meet them.
  
• GEN Hall of Shame
  Meet the Congressional enemies of research funding.
  
• Largest U.S. Biotech Clusters Faced Similar Challenges This Year as Seen Elsewhere
  California, Massachusetts, North Carolina, and Maryland have had to find ways to deal with lower funding and attract more firms.
  
• Cliff Spells Danger for Biotechs
  If Obama and Congress cannot agree, key agencies face cuts while tax changes would dampen new investment.
  
• 7 Biotech Trends for the Coming Year
  What does 2013 hold for the industry?
  
• No Passage to India
  Private investment dearth clouds the future of the subcontinent’s fast-growing biopharma industry.
  
• A Look at the Top Two Bio Clusters in the U.S.: California and Massachusetts
  Financing and workforce issues are at the top of their agendas for this year.
  
• Review of the Second Tier of Biotechnology Clusters in the U.S.
  Colorado, Florida, New Jersey, Pennsylvania, and Washington gear up to boost growth plans while trying to balance budget woes.